Evaluating  ||| S:0 E:11 ||| VBG
iatrogenic  ||| S:11 E:22 ||| JJ
prescribing ||| S:22 E:33 ||| NN
:  ||| S:33 E:35 ||| :
development  ||| S:35 E:47 ||| NN
of  ||| S:47 E:50 ||| IN
an  ||| S:50 E:53 ||| DT
oncology-focused  ||| S:53 E:70 ||| JJ
trigger  ||| S:70 E:78 ||| NN
tool  ||| S:78 E:83 ||| NN
Drug-related  ||| S:83 E:96 ||| JJ
iatrogenic  ||| S:96 E:107 ||| JJ
effects  ||| S:107 E:115 ||| NNS
are  ||| S:115 E:119 ||| VBP
common  ||| S:119 E:126 ||| JJ
in  ||| S:126 E:129 ||| IN
oncology  ||| S:129 E:138 ||| NN
because  ||| S:138 E:146 ||| IN
chemotherapy  ||| S:146 E:159 ||| NN
is  ||| S:159 E:162 ||| VBZ
toxic ||| S:162 E:167 ||| JJ
.  ||| S:167 E:169 ||| .
The  ||| S:169 E:173 ||| DT
evaluation  ||| S:173 E:184 ||| NN
of  ||| S:184 E:187 ||| IN
the  ||| S:187 E:191 ||| DT
application  ||| S:191 E:203 ||| NN
of  ||| S:203 E:206 ||| IN
the  ||| S:206 E:210 ||| DT
guidelines  ||| S:210 E:221 ||| NNS
may  ||| S:221 E:225 ||| MD
be  ||| S:225 E:228 ||| VB
a  ||| S:228 E:230 ||| DT
way  ||| S:230 E:234 ||| NN
to  ||| S:234 E:237 ||| TO
understand  ||| S:237 E:248 ||| VB
the  ||| S:248 E:252 ||| DT
occurrence  ||| S:252 E:263 ||| NN
of  ||| S:263 E:266 ||| IN
adverse  ||| S:266 E:274 ||| JJ
drug-related  ||| S:274 E:287 ||| JJ
event  ||| S:287 E:293 ||| NN
( ||| S:293 E:294 ||| -LRB-
ADE ||| S:294 E:297 ||| NNP
) ||| S:297 E:298 ||| -RRB-
.  ||| S:298 E:300 ||| .
There  ||| S:300 E:306 ||| EX
is  ||| S:306 E:309 ||| VBZ
no  ||| S:309 E:312 ||| DT
specific  ||| S:312 E:321 ||| JJ
method  ||| S:321 E:328 ||| NN
for  ||| S:328 E:332 ||| IN
identifying  ||| S:332 E:344 ||| VBG
ADEs  ||| S:344 E:349 ||| JJ
and  ||| S:349 E:353 ||| CC
measuring  ||| S:353 E:363 ||| VBG
harm  ||| S:363 E:368 ||| NN
to  ||| S:368 E:371 ||| TO
patients  ||| S:371 E:380 ||| NNS
in  ||| S:380 E:383 ||| IN
oncology ||| S:383 E:391 ||| NN
.  ||| S:391 E:393 ||| .
Our  ||| S:393 E:397 ||| PRP$
objective  ||| S:397 E:407 ||| NN
was  ||| S:407 E:411 ||| VBD
to  ||| S:411 E:414 ||| TO
develop  ||| S:414 E:422 ||| VB
and  ||| S:422 E:426 ||| CC
test  ||| S:426 E:431 ||| VB
an  ||| S:431 E:434 ||| DT
Oncology  ||| S:434 E:443 ||| NNP
Trigger  ||| S:443 E:451 ||| NNP
Tool  ||| S:451 E:456 ||| NNP
( ||| S:456 E:457 ||| -LRB-
OTT ||| S:457 E:460 ||| NNP
)  ||| S:460 E:462 ||| -RRB-
for  ||| S:462 E:466 ||| IN
ADEs  ||| S:466 E:471 ||| JJ
and  ||| S:471 E:475 ||| CC
to  ||| S:475 E:478 ||| TO
describe  ||| S:478 E:487 ||| VB
ADE  ||| S:487 E:491 ||| JJ
characteristics  ||| S:491 E:507 ||| NNS
and  ||| S:507 E:511 ||| CC
incidence ||| S:511 E:520 ||| NN
.  ||| S:520 E:522 ||| .
A  ||| S:522 E:524 ||| DT
clinical  ||| S:524 E:533 ||| JJ
advisory  ||| S:533 E:542 ||| JJ
panel  ||| S:542 E:548 ||| NN
identified  ||| S:548 E:559 ||| VBN
situations  ||| S:559 E:570 ||| NNS
at  ||| S:570 E:573 ||| IN
high  ||| S:573 E:578 ||| JJ
risk  ||| S:578 E:583 ||| NN
of  ||| S:583 E:586 ||| IN
ADE  ||| S:586 E:590 ||| NNP
occurrence  ||| S:590 E:601 ||| NN
and  ||| S:601 E:605 ||| CC
built  ||| S:605 E:611 ||| VBD
22  ||| S:611 E:614 ||| CD
triggers  ||| S:614 E:623 ||| NN
with ||| S:623 E:627 ||| IN
,  ||| S:627 E:629 ||| ,
in  ||| S:629 E:632 ||| IN
each  ||| S:632 E:637 ||| DT
case ||| S:637 E:641 ||| NN
,  ||| S:641 E:643 ||| ,
an  ||| S:643 E:646 ||| DT
analysis  ||| S:646 E:655 ||| NN
flowchart  ||| S:655 E:665 ||| NN
to  ||| S:665 E:668 ||| TO
confirm  ||| S:668 E:676 ||| VB
or  ||| S:676 E:679 ||| CC
refute  ||| S:679 E:686 ||| JJ
occurrence ||| S:686 E:696 ||| NN
.  ||| S:696 E:698 ||| .
The  ||| S:698 E:702 ||| DT
OTT  ||| S:702 E:706 ||| NNP
was  ||| S:706 E:710 ||| VBD
used  ||| S:710 E:715 ||| VBN
to  ||| S:715 E:718 ||| TO
review  ||| S:718 E:725 ||| VB
288  ||| S:725 E:729 ||| CD
random  ||| S:729 E:736 ||| JJ
admissions  ||| S:736 E:747 ||| NNS
( ||| S:747 E:748 ||| -LRB-
Oct.  ||| S:748 E:753 ||| NNP
2010-Sept.  ||| S:753 E:764 ||| CD
2011 ||| S:764 E:768 ||| CD
)  ||| S:768 E:770 ||| -RRB-
and  ||| S:770 E:774 ||| CC
measure  ||| S:774 E:782 ||| NN
ADE  ||| S:782 E:786 ||| NNP
incidence  ||| S:786 E:796 ||| NN
and  ||| S:796 E:800 ||| CC
severity  ||| S:800 E:809 ||| NN
( ||| S:809 E:810 ||| -LRB-
CTCAE  ||| S:810 E:816 ||| NNP
4.03  ||| S:816 E:821 ||| CD
-  ||| S:821 E:823 ||| :
Common  ||| S:823 E:830 ||| NNP
Terminology  ||| S:830 E:842 ||| NNP
Criteria  ||| S:842 E:851 ||| NNP
for  ||| S:851 E:855 ||| IN
Adverse  ||| S:855 E:863 ||| JJ
Events ||| S:863 E:869 ||| NNS
) ||| S:869 E:870 ||| -RRB-
.  ||| S:870 E:872 ||| .
Tool  ||| S:872 E:877 ||| NN
feasibility  ||| S:877 E:889 ||| NN
( ||| S:889 E:890 ||| -LRB-
time  ||| S:890 E:895 ||| NN
required ||| S:895 E:903 ||| VBN
) ||| S:903 E:904 ||| -RRB-
,  ||| S:904 E:906 ||| ,
inter-rater  ||| S:906 E:918 ||| NNP
( ||| S:918 E:919 ||| -LRB-
IR ||| S:919 E:921 ||| NNP
)  ||| S:921 E:923 ||| -RRB-
reproducibility  ||| S:923 E:939 ||| NN
and  ||| S:939 E:943 ||| CC
positive  ||| S:943 E:952 ||| JJ
predictive  ||| S:952 E:963 ||| JJ
value  ||| S:963 E:969 ||| NN
( ||| S:969 E:970 ||| -LRB-
PPV ||| S:970 E:973 ||| NNP
)  ||| S:973 E:975 ||| -RRB-
were  ||| S:975 E:980 ||| VBD
measured ||| S:980 E:988 ||| VBN
.  ||| S:988 E:990 ||| .
Overall ||| S:990 E:997 ||| RB
,  ||| S:997 E:999 ||| ,
884  ||| S:999 E:1003 ||| CD
triggers  ||| S:1003 E:1012 ||| NNS
were  ||| S:1012 E:1017 ||| VBD
detected  ||| S:1017 E:1026 ||| VBN
and  ||| S:1026 E:1030 ||| CC
122  ||| S:1030 E:1034 ||| CD
ADEs ||| S:1034 E:1038 ||| NN
,  ||| S:1038 E:1040 ||| ,
with  ||| S:1040 E:1045 ||| IN
42.4  ||| S:1045 E:1050 ||| NNP
ADEs ||| S:1050 E:1054 ||| NNP
/ ||| S:1054 E:1055 ||| CD
100  ||| S:1055 E:1059 ||| CD
admissions  ||| S:1059 E:1070 ||| NNS
or  ||| S:1070 E:1073 ||| CC
46.0  ||| S:1073 E:1078 ||| NNP
ADEs ||| S:1078 E:1082 ||| NNP
/ ||| S:1082 E:1083 ||| CD
1000  ||| S:1083 E:1088 ||| CD
patient-days ||| S:1088 E:1100 ||| NN
,  ||| S:1100 E:1102 ||| ,
and  ||| S:1102 E:1106 ||| CC
a  ||| S:1106 E:1108 ||| DT
31.1 ||| S:1108 E:1112 ||| CD
%  ||| S:1112 E:1114 ||| NN
rate  ||| S:1114 E:1119 ||| NN
of  ||| S:1119 E:1122 ||| IN
severe  ||| S:1122 E:1129 ||| JJ
ADEs ||| S:1129 E:1133 ||| NN
.  ||| S:1133 E:1135 ||| .
The  ||| S:1135 E:1139 ||| DT
most  ||| S:1139 E:1144 ||| RBS
common  ||| S:1144 E:1151 ||| JJ
ADEs  ||| S:1151 E:1156 ||| NN
were  ||| S:1156 E:1161 ||| VBD
hyperglycaemia  ||| S:1161 E:1176 ||| NNS
( ||| S:1176 E:1177 ||| -LRB-
14.5 ||| S:1177 E:1181 ||| CD
% ||| S:1181 E:1182 ||| NN
) ||| S:1182 E:1183 ||| -RRB-
,  ||| S:1183 E:1185 ||| ,
unplanned  ||| S:1185 E:1195 ||| JJ
drug-related  ||| S:1195 E:1208 ||| JJ
admission  ||| S:1208 E:1218 ||| NN
within  ||| S:1218 E:1225 ||| IN
30  ||| S:1225 E:1228 ||| CD
days  ||| S:1228 E:1233 ||| NNS
( ||| S:1233 E:1234 ||| -LRB-
13.7 ||| S:1234 E:1238 ||| CD
% ||| S:1238 E:1239 ||| NN
)  ||| S:1239 E:1241 ||| -RRB-
and  ||| S:1241 E:1245 ||| CC
opiate-induced  ||| S:1245 E:1260 ||| JJ
constipation  ||| S:1260 E:1273 ||| NNS
( ||| S:1273 E:1274 ||| -LRB-
12.1 ||| S:1274 E:1278 ||| CD
% ||| S:1278 E:1279 ||| NN
) ||| S:1279 E:1280 ||| -RRB-
.  ||| S:1280 E:1282 ||| .
Unplanned  ||| S:1282 E:1292 ||| JJ
drug-related  ||| S:1292 E:1305 ||| JJ
admission  ||| S:1305 E:1315 ||| NN
was  ||| S:1315 E:1319 ||| VBD
the  ||| S:1319 E:1323 ||| DT
most  ||| S:1323 E:1328 ||| RBS
serious  ||| S:1328 E:1336 ||| JJ
( ||| S:1336 E:1337 ||| -LRB-
82.4 ||| S:1337 E:1341 ||| NNP
%  ||| S:1341 E:1343 ||| NN
incidence  ||| S:1343 E:1353 ||| NN
of  ||| S:1353 E:1356 ||| IN
severe  ||| S:1356 E:1363 ||| JJ
harm ||| S:1363 E:1367 ||| NN
) ||| S:1367 E:1368 ||| -RRB-
.  ||| S:1368 E:1370 ||| .
Mean  ||| S:1370 E:1375 ||| JJ
time  ||| S:1375 E:1380 ||| NN
for  ||| S:1380 E:1384 ||| IN
OTT  ||| S:1384 E:1388 ||| NNP
implementation  ||| S:1388 E:1403 ||| NN
was  ||| S:1403 E:1407 ||| VBD
21.8  ||| S:1407 E:1412 ||| CD
min ||| S:1412 E:1415 ||| NNS
;  ||| S:1415 E:1417 ||| :
IR  ||| S:1417 E:1420 ||| NNP
reproducibility  ||| S:1420 E:1436 ||| NN
was  ||| S:1436 E:1440 ||| VBD
high  ||| S:1440 E:1445 ||| JJ
( ||| S:1445 E:1446 ||| -LRB-
κ=0.965  ||| S:1446 E:1454 ||| NNP
( ||| S:1454 E:1455 ||| -LRB-
trigger ||| S:1455 E:1462 ||| NN
) ||| S:1462 E:1463 ||| -RRB-
;  ||| S:1463 E:1465 ||| :
κ=0.935  ||| S:1465 E:1473 ||| CD
( ||| S:1473 E:1474 ||| -LRB-
ADE ||| S:1474 E:1477 ||| NNP
) ||| S:1477 E:1478 ||| -RRB-
;  ||| S:1478 E:1480 ||| :
κ=0.853  ||| S:1480 E:1488 ||| CD
( ||| S:1488 E:1489 ||| -LRB-
harm ||| S:1489 E:1493 ||| NN
) ||| S:1493 E:1494 ||| -RRB-
) ||| S:1494 E:1495 ||| -RRB-
;  ||| S:1495 E:1497 ||| :
PPV  ||| S:1497 E:1501 ||| NNP
22-trigger  ||| S:1501 E:1512 ||| NNP
version  ||| S:1512 E:1520 ||| NN
was  ||| S:1520 E:1524 ||| VBD
20.7 ||| S:1524 E:1528 ||| CD
% ||| S:1528 E:1529 ||| NN
.  ||| S:1529 E:1531 ||| .
ADE  ||| S:1531 E:1535 ||| NNP
analysis  ||| S:1535 E:1544 ||| NN
flowcharts  ||| S:1544 E:1555 ||| VBZ
coupled  ||| S:1555 E:1563 ||| VBN
with  ||| S:1563 E:1568 ||| IN
standardised  ||| S:1568 E:1581 ||| JJ
grading  ||| S:1581 E:1589 ||| NN
of  ||| S:1589 E:1592 ||| IN
harm  ||| S:1592 E:1597 ||| NN
considerably  ||| S:1597 E:1610 ||| RB
reduced  ||| S:1610 E:1618 ||| VBN
IR  ||| S:1618 E:1621 ||| NNP
variability ||| S:1621 E:1632 ||| NN
,  ||| S:1632 E:1634 ||| ,
thus  ||| S:1634 E:1639 ||| RB
providing  ||| S:1639 E:1649 ||| VBG
a  ||| S:1649 E:1651 ||| DT
robust  ||| S:1651 E:1658 ||| JJ
oncology-focused  ||| S:1658 E:1675 ||| JJ
trigger  ||| S:1675 E:1683 ||| NN
tool  ||| S:1683 E:1688 ||| NN
for  ||| S:1688 E:1692 ||| IN
use  ||| S:1692 E:1696 ||| NN
in  ||| S:1696 E:1699 ||| IN
ADE  ||| S:1699 E:1703 ||| NNP
audits  ||| S:1703 E:1710 ||| NN
and  ||| S:1710 E:1714 ||| CC
hospital  ||| S:1714 E:1723 ||| NN
comparisons ||| S:1723 E:1734 ||| NNS
.  ||| S:1734 E:1736 ||| .
The  ||| S:1736 E:1740 ||| DT
involvement  ||| S:1740 E:1752 ||| NN
of  ||| S:1752 E:1755 ||| IN
a  ||| S:1755 E:1757 ||| DT
clinical  ||| S:1757 E:1766 ||| JJ
advisory  ||| S:1766 E:1775 ||| JJ
panel  ||| S:1775 E:1781 ||| NN
in  ||| S:1781 E:1784 ||| IN
tool  ||| S:1784 E:1789 ||| NN
development  ||| S:1789 E:1801 ||| NN
should  ||| S:1801 E:1808 ||| MD
help  ||| S:1808 E:1813 ||| VB
drive  ||| S:1813 E:1819 ||| NN
changes  ||| S:1819 E:1827 ||| NNS
for  ||| S:1827 E:1831 ||| IN
improving  ||| S:1831 E:1841 ||| VBG
practice ||| S:1841 E:1849 ||| NN
.  ||| S:1849 E:1851 ||| .
Further  ||| S:1851 E:1859 ||| JJ
research  ||| S:1859 E:1868 ||| NN
on  ||| S:1868 E:1871 ||| IN
the  ||| S:1871 E:1875 ||| DT
OTT  ||| S:1875 E:1879 ||| NNP
is  ||| S:1879 E:1882 ||| VBZ
warranted ||| S:1882 E:1891 ||| VBN
.  ||| S:1891 E:1893 ||| .
